Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
about
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failureHeart failure in subjects with chronic kidney disease: Best management practices.Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice.Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure.Beta-blocker therapy of heart failure: an update.Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.Nebivolol in the treatment of chronic heart failure.Use of guideline-recommended therapies for heart failure in the Medicare population.Noncardiac comorbidities and acute heart failure patients.Plasma renin and cardiovascular risk: what is the evidence for an association?Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results.Radionuclide imaging of neurohormonal system of the heartI-1-deficiency negatively impacts survival in a cardiomyopathy mouse model.The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.Relationships among achieved heart rate, β-blocker dose and long-term outcomes in patients with heart failure with atrial fibrillationTreatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy.EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot).Monitoring and adverse events in relation to ACE inhibitor/angiotensin receptor blocker initiation in people with diabetes in general practice: a population database study.Implementation of beta-blockade in elderly heart failure patients: role of the nurse specialist.Renal function monitoring in heart failure - what is the optimal frequency? A narrative review.Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with theAre hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry
P2860
Q34068712-F23810C0-0857-4919-A5CD-AC12930AF48FQ34390665-71129203-A499-41C9-8644-635D0D8805D9Q35101841-939330AC-BC53-4A8C-B90C-6D1BAA39DC5EQ35748736-F7B04580-4DB9-4EA8-82D7-83D693572A84Q36723828-DD1A2BCB-63F0-4FD4-BA68-AAB47DF32BC4Q36811824-91938384-E196-4CE5-A4E3-469D4FD4B313Q37031362-FFCAEBF7-341A-4C6C-8ED5-EAB8C7F0021EQ37087394-18263B25-F614-4468-A0BF-EF8BA7ECB8E1Q37531314-9A3291BC-BAE3-496C-A87A-514CF672770FQ38103400-B874DCAE-A733-4EC3-8266-B729D81B3C9AQ38279998-268AACF5-CBC4-4B79-A496-8DC6665DA0C8Q38397104-F8FEE4F4-2EE9-4935-B6E0-1EF8D0C98827Q38635697-7572902F-28A2-4861-8D43-21CB980BB043Q38817384-1927FDDF-64CF-4B56-B2F5-B1E22F2E6648Q39024503-860959F0-2FDE-49F6-B17C-2B699BC9D3A5Q41607888-F74560FA-64F1-4EC4-B3F8-80833B222B68Q41899817-4F15023C-33E2-4260-95B9-36C9E244883FQ43596338-BBF9A6E6-8A2C-4B9E-9A93-F0F754B5A61FQ46414626-310AC44B-4490-4B3F-B7CA-E1657DEA3795Q46757983-82014ADD-45A4-4C7B-B7FD-BD66E2038283Q46897948-9E7181CF-2801-4A6D-BB63-CCBBBF67F62CQ47140028-E0E1C970-5E65-4FA6-B19E-8067CF43A72CQ48615907-E5E8E739-3BEC-41BF-921F-142ED5B07192Q55050673-3F4951CB-467E-4365-9711-41DBB6C3F9EBQ57628639-054CF18F-6ECB-4F10-9791-03E6CC8CAE5C
P2860
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Practical recommendations for ...... ting guidelines into practice.
@en
Practical recommendations for ...... ting guidelines into practice.
@nl
type
label
Practical recommendations for ...... ting guidelines into practice.
@en
Practical recommendations for ...... ting guidelines into practice.
@nl
prefLabel
Practical recommendations for ...... ting guidelines into practice.
@en
Practical recommendations for ...... ting guidelines into practice.
@nl
P2093
P2860
P50
P1476
Practical recommendations for ...... ting guidelines into practice.
@en
P2093
Aldo Maggioni
Eric Eichhorn
Ileana L Piña
Jordi Soler-Soler
Leif Erhardt
Rainer Dietz
Robert S McKelvie
P2860
P304
P356
10.1016/J.EJHEART.2005.07.002
P577
2005-08-01T00:00:00Z